Figure 1. CDDO-Me induces Nqo1 expression and activation
(a) Pharmacological mechanism of CDDO-Me in Nrf2 activation. (b) Expression of Nqo1 mRNA in Hepa1c1c7 murine hepatoma cells after treatment with the indicated concentrations of CDDO-Me for 6, 24, or 48 h determined using quantitative PCR (mean + S.D., duplicate). (c) NQO1 enzyme activity in Hepa1c1c7 cells after treatment with the indicated concentrations of CDDO-Me (mean ± S.D., triplicate); EC150 was calculated from the activities. (d) Expression of Nqo1 mRNA in the livers of C57BL/6J mice after a single oral administration of CDDO-Me at 3 mg・kg-1 or 10 mg・kg-1 (mean ± S.D., triplicate). (e) The concentrations of plasma CDDO-Me in C57BL/6J mice after a single oral administration of CDDO-Me at 3 mg・kg-1 or 10 mg・kg-1 (mean ± S.D., triplicate).